This article was originally published here
Cancer Med. October 9, 2021. doi: 10.1002 / cam4.4319. Online ahead of print.
Prostate cancer is the third most common cancer in Malaysia with a lifetime risk of 1 in 117 men. Here we launched a longitudinal study of prostate cancer in Malaysia (M-CaP) to investigate the characteristics clinical and tumor, treatment regimens as well as disease outcomes of multiethnic Asian men in a real-world setting. The M-CaP database included 1,839 new prostate cancer patients diagnosed between 2016 and 2018 at nine public urology reference centers across Malaysia. Baseline demographic and clinical parameters, tumor characteristics, primary treatment, follow-up, and vital status data were prospectively retrieved from inpatient case notes or electronic medical records. The primary endpoints were overall survival (OS) and biochemical progression-free survival (bPFS). The median age at diagnosis for M-CaP patients was 70 years (interquartile range, IQR 65-75). The majority of patients were Chinese (831, 45.2%), followed by Malays (704, 38.3%), Indians (124, 6.7%) and other races (181, 9.8%) . The median follow-up for all patients was 23.5 months (IQR 15.9-33.6). Although 58.1% had advanced stage cancer, we observed ethnic and geographic disparities in the diagnosis of advanced stage prostate cancer. Curative radiotherapy and primary androgen deprivation therapy were the most common treatments for stage III and IV disease, respectively. The median OS and bPSS of stage IV patients were 40.1 months and 19.2 months (95% CI 17.6-20.8), respectively. The late stage of presentation remains a challenge in multiethnic Asian men. Early detection is imperative to improve treatment outcomes and survival for patients with prostate cancer.